BioSpace News Archive

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced the online publication of the manuscript, “Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer” in Clinical Cancer Research,

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced the publication of a research article that was produced in collaboration with uveitis Key Opinion Leaders, including Prof. de Smet, Prof. Cunningham, Dr. Newmann, and Dr. Kramer.

Levitee Labs Inc. (CSE: LVT) (the “Company” or “Levitee”), a biotechnology company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that it has completed the acquisition of all the issued and outstanding shares of telemedicine company BlockMD Ltd. (“BlockMD”) as of July 27, 2021.

The medical photobiostimulation system market is projected to reach US$ 314.88 million by 2028 from US$ 204.66 million in 2021; it is expected to grow at a CAGR of 6.3% from 2021 to 2028.

Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform.

The Medical Scheduling Software in healthcare market was valued at US$ 267.83 million in 2018 and it is projected to reach US$ 789.56 million by 2027; it is expected to grow at a CAGR of 13.0% from 2018 to 2027.

The patient temperature monitoring market was valued at US$ 2,946.47 million in 2019 and is expected reach US$ 4,386.01 million in 2027; it is projected to grow at a CAGR of 5.2% from 2020 to 2027.

Tricida, Inc. announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021.

Xenetic Biosciences, Inc. announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock at a purchase price per share of $2.70, priced at-the-market under Nasdaq rules.

Ampio Pharmaceuticals (NYSE American: AMPE), today announced details on the Company’s abstract presentation, “Significant Inhibition of the TLR7/CXCL10 Signaling Axis by LMWF5A in Monocytic Lineages; Implications for COVID-19 and Lupus Nephritis,”